Codex DNA, Inc. (DNAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
DNAY POWR Grades
- Sentiment is the dimension where DNAY ranks best; there it ranks ahead of 97.86% of US stocks.
- DNAY's strongest trending metric is Growth; it's been moving down over the last 131 days.
- DNAY ranks lowest in Quality; there it ranks in the 3rd percentile.
DNAY Stock Summary
- With a one year PEG ratio of 0.54, TELESIS BIO INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.04% of US stocks.
- TELESIS BIO INC's stock had its IPO on June 18, 2021, making it an older stock than merely 4.64% of US equities in our set.
- The volatility of TELESIS BIO INC's share price is greater than that of 96.79% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to TELESIS BIO INC, a group of peers worth examining would be BJDX, GEOS, PHAR, AIM, and HSTO.
- To dig deeper into the stock's financial statements, go to DNAY's page on browse-edgar?action=getcompany&CIK=0001850079.
DNAY Valuation Summary
- In comparison to the median Healthcare stock, DNAY's price/sales ratio is 60.42% lower, now standing at 1.9.
- DNAY's price/sales ratio has moved down 77.5 over the prior 18 months.
Below are key valuation metrics over time for DNAY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DNAY | 2022-12-05 | 1.9 | 0.7 | -0.7 | -0.7 |
| DNAY | 2022-12-02 | 1.9 | 0.8 | -0.8 | -0.7 |
| DNAY | 2022-12-01 | 1.9 | 0.8 | -0.8 | -0.7 |
| DNAY | 2022-11-30 | 2.0 | 0.8 | -0.8 | -0.8 |
| DNAY | 2022-11-29 | 2.0 | 0.8 | -0.8 | -0.7 |
| DNAY | 2022-11-28 | 2.0 | 0.8 | -0.8 | -0.7 |
DNAY Price Target
For more insight on analysts targets of DNAY, see our DNAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.50 | Average Broker Recommendation | 1.33 (Strong Buy) |
DNAY Stock Price Chart Interactive Chart >
DNAY Price/Volume Stats
| Current price | $1.20 | 52-week high | $11.32 |
| Prev. close | $1.13 | 52-week low | $1.08 |
| Day low | $1.10 | Volume | 43,463 |
| Day high | $1.22 | Avg. volume | 323,550 |
| 50-day MA | $1.61 | Dividend yield | N/A |
| 200-day MA | $3.28 | Market Cap | 35.43M |
Codex DNA, Inc. (DNAY) Company Bio
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Latest DNAY News From Around the Web
Below are the latest news stories about TELESIS BIO INC that investors may wish to consider to help them evaluate DNAY as an investment opportunity.
Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call TranscriptTelesis Bio, Inc. (NASDAQ:NASDAQ:DNAY) Q3 2022 Earnings Conference Call November 08, 2022, 16:30 ET Company Participants Todd Nelson - CEO Brent Hunter - VP, Finance Conference Call… |
Telesis Bio, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportAs you might know, Telesis Bio, Inc. ( NASDAQ:DNAY ) just kicked off its latest third-quarter results with some very... |
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue EstimatesCodex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. |
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live |
DNAY Price Returns
| 1-mo | -28.14% |
| 3-mo | -37.50% |
| 6-mo | -62.03% |
| 1-year | -83.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -88.89% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...